The Next Revolution in Precision Medicine
LinusBio, a pioneering platform company, is developing precision exposome biomarkers to enable earlier diagnoses, enhance patient monitoring, and accelerate drug development.
Discover more
Our propietary technology
Temporal exposomics sequencing powering novel biomarkers.
-
The LinusBio platform maps the growth rings in hair to reveal thousands of molecular features at multiple time points. A single assay provides as much information as hundreds of blood tests, taken over years, revealing how biology changes over time.
Go to platform -
Leveraging proprietary robotics and laser systems, our platform releases complex biomolecules, analyzes them with mass spectrometry and runs the data through a powerful AI pipeline, identifying molecular signatures no other assays can find. These biomarkers can be used to rapidly and comprehensively facilitate discovery across central nervous system disorders, gastrointestinal diseases, cancer and other conditions.
Our Science -
LinusBio has created an AI-powered pipeline and a one-of-a-kind global dataset that transforms exposomic readouts into meaningful insights. By harnessing big data and AI, we uncover biological pathways and mechanisms to drive target discovery.
Go to pipeline
Our science
LinusBio has developed a cutting-edge exposomic platform to better understand diseases and their pathogenesis.
ClearStrand-ASD Now Available
A non-invasive diagnostic aid for Autism Spectrum Disorder. Our mission is to empower healthcare providers and families in making informed choices for their child's care. Rx Only.
It all begins with a single strand of hair
Discover our platform
A comprehensive pipeline
Our pipeline unites precision exposomic biomarkers with target discovery to advance precision medicine
LinusBio has developed the first molecular autism spectrum disorder (ASD) diagnostic biomarker - StrandDx. The test has received FDA Breakthrough designation and can identify a biomarker associated with ASD in children as young as one month. Our rule-out diagnostic aid, ClearStrand-ASD, is now commercially available. Early diagnosis means better care.
Alongside this, LinusBio’s researchers are developing advanced tests for other central nervous system disorders, including Amyotrophic Lateral Sclerosis (ALS), Attention Deficit Hyperactivity Disorder (ADHD), and Schizophrenia or Psychosis.
View full pipeline
Featured projects
LinusBio has developed the first molecular autism spectrum disorder (ASD) diagnostic biomarker - StrandDx. The test has received FDA Breakthrough designation and can identify a biomarker associated with ASD in children as young as one month. Our rule-out diagnostic aid, ClearStrand-ASD, is now commercially available. Early diagnosis means better care.
Alongside this, LinusBio’s researchers are developing advanced tests for other central nervous system disorders, including Amyotrophic Lateral Sclerosis (ALS), Attention Deficit Hyperactivity Disorder (ADHD), and Schizophrenia or Psychosis.
View full pipeline
01
Early Autism Detection - ClearStrand-ASD
ClearStrand-ASD is a non-invasive test that detects a biomarker associated with autism using a strand of hair.
-
Patent
submitted -
Clinical
studies -
Pathway
characterization -
Commercially
available
-
Patent
submitted -
Clinical
studies -
Pathway
characterization -
Commercially
available
02
Attention Deficit Hyperactive Disorder
In development
-
Patent
submitted -
Clinical
studies -
Pathway
characterization -
Commercially
available
-
Patent
submitted -
Clinical
studies -
Pathway
characterization -
Commercially
available
03
Psychosis and Schizophrenia
In development
-
Patent
submitted -
Clinical
studies -
Pathway
characterization -
Commercially
available
-
Patent
submitted -
Clinical
studies -
Pathway
characterization -
Commercially
available
“We are a group of individuals shaping LinusBio's mission to transform healthcare through groundbreaking research and development.”
Meet the team
Partnerships
Collaborate in leading the future of healthcare
Partnerships
Collaborate in leading the future of healthcare
LinusBio’s world-class team of scientists, engineers, and clinical experts is redefining the future of precision medicine. With decades of collective experience in biotechnology, data science, and environmental health, our leadership has pioneered groundbreaking methodologies like temporal exposomic sequencing.
Partner with us
News
Our latest news and events
Groundbreaking Autism Biomarker: LinusBio Launches ClearStrand-ASD to aid Health Care Providers in Ruling Out Autism Using a Single Strand of Hair
